Slide 1: Results Q2 2007 Conference Call
Results Q2 2007 Conference Call July 30, 2007 | 2:00 p.m. (CET) Dr. Axel Herberg, CEO Hans-Jürgen Wiecha, CFO 0
Slide 2: Agenda
Agenda Recent Developments Dr. Axel Herberg, CEO Business Highlights Q2 2007 Dr. Axel Herberg, CEO Financial Overview Q2 2007 / H1 2007 Hans-Jürgen Wiecha, CFO Outlook Dr. Axel Herberg, CEO 1
Slide 3: Recent Developments
Recent Developments Successful IPO on June 11, 2007 Listing in the Prime Standard Segment of the Frankfurt Stock Exchange Placement of 22.8m shares (o/w 11.4m primary shares) Gross proceeds of &456m which significantly enhance the financial flexibility Actual free float of 72.6% as per July 30, 2007
Slide 4: Agenda
Agenda Recent Developments Dr. Axel Herberg, CEO Business Highlights Q2 2007 Dr. Axel Herberg, CEO Financial Overview Q2 2007 / H1 2007 Hans-Jürgen Wiecha, CFO Outlook Dr. Axel Herberg, CEO 3
Slide 5: Business Highlights Q2 2007: Snapshot
Business Highlights Q2 2007: Snapshot Another strong quarter for Gerresheimer AG: Benefits from high growth rates in the Pharma/Life Science Research and Cosmetic markets Our strategically enhanced product portfolio and strong operational performance resulted in considerable Sales and Adjusted EBITD
Slide 6: Business Highlights Q2 2007: Divisional Overview
Business Highlights Q2 2007: Divisional Overview Good performance of all business segments: Tubular Glass: Installation of second RTF line Strong sales increase with syringes Continued sales growth in vials and ampoules Plastic Systems: Wilden integration is proceeding well Improved production perfo
Slide 7: Agenda
Agenda Recent Developments Dr. Axel Herberg, CEO Business Highlights Q2 2007 Dr. Axel Herberg, CEO Financial Overview Q2 2007 / H1 2007 Hans-Jürgen Wiecha, CFO Outlook Dr. Axel Herberg, CEO 6
Slide 8: Financial Overview Q2 2007 / H1 2007: Gerresheimer Group
Financial Overview Q2 2007 / H1 2007 Gerresheimer Group Strong organic growth and growth from Wilden acquisition Net Sales and Adjusted EBITDA =m 1) Adj. EBITDA margin: Adj. EBITDA margin: Organic growth: 6.9% 1) Q2 2006: 18.2% Organic growth: 7.7% H1 2006: 17.0% Q2 2007: 18.2% H1 2007: 18.0% 245.0
Slide 9: Financial Overview: Tubular Glass
Financial Overview Q2 2007 / H1 2007 Tubular Glass Strong organic growth in all product lines, especially syringes Adjusted EBITDA decline in Q2/2007 caused by planned furnace overhauls and expected start-up costs of a new RTF-line Net Sales and Adjusted EBITDA =m 1) Adj. EBITDA margin: Adj. EBITDA
Slide 10: Financial Overview: Plastic Systems
Financial Overview Q2 2007 / H1 2007 Plastic Systems Wilden integration proceeding well Continued growth in all product segments Net Sales and Adjusted EBITDA =m 1) Adj. EBITDA margin: Adj. EBITDA margin: Organic growth: 4.6% 1) Q2 2006: 23.9% Organic growth: 4.8% H1 2006: 22.7% Q2 2007: 18.5% H1 20
Slide 11: Financial Overview: Moulded Glass
Financial Overview Q2 2007 / H1 2007 Moulded Glass Strong sales growth in pharma and cosmetics Strong productivity improvements, especially in our US and Belgium operations Net Sales and Adjusted EBITDA =m 1) Adj. EBITDA margin: Adj. EBITDA margin: Organic growth: 11.8% 1) Q2 2006: 15.2% Organic gro
Slide 12: Financial Overview: Life Science Research
Financial Overview Q2 2007 / H1 2007 Life Science Research Stable sales and margin development New joint venture will lead to market and production synergies Net Sales and Adjusted EBITDA =m 1) Adj. EBITDA margin: Adj. EBITDA margin: Organic growth: 0.3% 1) Q2 2006: 10.1% Organic growth: -0.9% H1 20
Slide 13: Summary Income Statement
Financial Overview Q2 2007 / H1 2007 Summary Income Statement New capital structure after IPO will improve net earnings change change (= m) Q2 2007 Q2 2006 in % H1 2007 H1 2006 in % Net Sales 245.0 170.5 +43.7 447.3 320.6 +39.5 Adjusted EBITDA1) 44.6 31.1 +43.4 80.3 54.5 +47.3 margin in % 18.2 18.2
Slide 14: Net Financial Debt
Financial Overview Q2 2007 / H1 2007: Net Financial Debt IPO deleveraged Gerresheimer significantly, thus providing more financial flexibility stated pro forma1) stated (= m) May 31, 2007 May 31, 2007 Nov 30, 2006 Senior Facilities 562.7 275.0 269.3 Senior Notes due 2015 210.0 126.0 210.0 Other Fina
Slide 15: Capex
Financial Overview Q2 2007 / H1 2007: Capex Capex level reflects enlarged business portfolio Expected investments of =95m - =100m due to growth projects &m &m 36.7 28.9 13.5 2.7 23.2 18.9 1.9 9.6 14.8 13.7 10.7 7.8 11.4 9,5 6.3 5.8 Q2 2006 Q2 2007 H1 2006 H1 2007 Tubular Glass Moulded Glass Plastic
Slide 16: Agenda
Agenda Recent Developments Dr. Axel Herberg, CEO Business Highlights Q2 2007 Dr. Axel Herberg, CEO Financial Overview Q2 2007 / H1 2007 Hans-Jürgen Wiecha, CFO Outlook Dr. Axel Herberg, CEO 15
Slide 17: Outlook FY 2007
Outlook FY 2007 Net Sales Organic growth of approx. 8 – 9% Adjusted EBITDA margin Close to 19% CAPEX Expected investments of &95m – &100m Portfolio optimization Ongoing market observation for value accretive M&A transactions 16
Slide 18: Financial Calendar 2007/2008
Financial Calendar 2007/2008 October 17, 2007 Interim Report Q3 2007 February 28, 2007 Full Year Results 2007 April 17, 2008 Annual General Meeting 17
Slide 19: Contact Details
Contact Details Investor Relations Phone: +49 211 6181 345 Fax: +49 211 6181 123 Email: investorrelations@gerresheimer.com Please visit our IR website: www.gerresheimer.com/ir 18
Slide 20: Disclaimer
Disclaimer This presentation may contain certain forward-looking statements, including assumptions, opinions and views of the Company or cited from third party sources. Various known and unknown risks, uncertainties and other factors could cause the actual results, financial position, development or